Materials and methods
neuromuscular dysfunction, dysplasia, anemia, paralysis, hip arthroplasty, infection, bony ankylosis, arthroplasty, hip deformity
DYSPLASIA, ANEMIA, WEST, INFECTION, DISEASES, ANKYLOSING SPONDYLITIS
This study was a single-center (Orthopedics, West China Hospital, Chengdu, China), prospective, randomized clinical controlled trial including participants aged 18–80 years old. This trial was approved by the Ethics Committee on Clinical Trials, West China Hospital of Sichuan University (HX-IRB-AF-12-V4.0). All patients provided written informed consent before participation. The study was registered in the Clinical Trial Registry (ChiCTR2200059968). The exclusion criteria were as follows: neuromuscular dysfunction, including paralysis, myolysis or abductor weaknes; active infection lesions; severe hip deformity and hip dysplasia with Cone grade 3 or 4; ankylosing spondylitis patients with bony ankylosis or severe stiffness; bilateral hip arthroplasty at the same time; severe internal and surgical diseases or weak physique; and poor expected compliance. In total, 67 potential test persons were scheduled to undergo primary THA, where 4 patients were ineligible and 3 patients declined participation. The remaining 60 patients were randomized into two groups, while 1 patient in the cTHA group was finally not allocated due to anemia (Fig. Consolidated standards of reporting trial (consort) diagram showing the flow of patients through robotic arm-assisted total hip arthroplasty (rTHA) versus conventional total hip arthroplasty (cTHA)